366 related articles for article (PubMed ID: 35586209)
1. Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors.
Tune BXJ; Sim MS; Poh CL; Guad RM; Woon CK; Hazarika I; Das A; Gopinath SCB; Rajan M; Sekar M; Subramaniyan V; Fuloria NK; Fuloria S; Batumalaie K; Wu YS
J Oncol; 2022; 2022():3249766. PubMed ID: 35586209
[TBL] [Abstract][Full Text] [Related]
2. The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma.
Scheau C; Badarau IA; Costache R; Caruntu C; Mihai GL; Didilescu AC; Constantin C; Neagu M
Anal Cell Pathol (Amst); 2019; 2019():9423907. PubMed ID: 31886121
[TBL] [Abstract][Full Text] [Related]
3. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
4. Positive Correlation between Matrix Metalloproteinases and Epithelial-to-Mesenchymal Transition and its Association with Clinical Outcome in Bladder Cancer Patients.
Singh R; Mandhani A; Agrawal V; Garg M
Cancer Microenviron; 2018 Jun; 11(1):23-39. PubMed ID: 29349669
[TBL] [Abstract][Full Text] [Related]
5. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
Kim IS; Yang WS; Kim CH
Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
[TBL] [Abstract][Full Text] [Related]
6. [The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis].
Fink K; Boratyński J
Postepy Hig Med Dosw (Online); 2012 Sep; 66():609-28. PubMed ID: 23001203
[TBL] [Abstract][Full Text] [Related]
7. DSTYK Promotes Metastasis and Chemoresistance
Zhang J; Miller Z; Musich PR; Thomas AE; Yao ZQ; Xie Q; Howe PH; Jiang Y
Front Pharmacol; 2020; 11():1250. PubMed ID: 32982725
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.
Radisky ES; Radisky DC
J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):201-12. PubMed ID: 20440544
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.
Radisky ES; Raeeszadeh-Sarmazdeh M; Radisky DC
J Cell Biochem; 2017 Nov; 118(11):3531-3548. PubMed ID: 28585723
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition.
Lin CY; Tsai PH; Kandaswami CC; Lee PP; Huang CJ; Hwang JJ; Lee MT
Cancer Sci; 2011 Apr; 102(4):815-27. PubMed ID: 21219539
[TBL] [Abstract][Full Text] [Related]
12. New insight in urological cancer therapy: From epithelial-mesenchymal transition (EMT) to application of nano-biomaterials.
He P; Dai Q; Wu X
Environ Res; 2023 Jul; 229():115672. PubMed ID: 36906272
[TBL] [Abstract][Full Text] [Related]
13. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
14. Regulation of matrix metalloproteinases: an overview.
Chakraborti S; Mandal M; Das S; Mandal A; Chakraborti T
Mol Cell Biochem; 2003 Nov; 253(1-2):269-85. PubMed ID: 14619979
[TBL] [Abstract][Full Text] [Related]
15. Brucine suppresses breast cancer metastasis via inhibiting epithelial mesenchymal transition and matrix metalloproteinases expressions.
Li M; Li P; Zhang M; Ma F
Chin J Integr Med; 2018 Jan; 24(1):40-46. PubMed ID: 28795388
[TBL] [Abstract][Full Text] [Related]
16. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Sakamoto T; Kobayashi S; Yamada D; Nagano H; Tomokuni A; Tomimaru Y; Noda T; Gotoh K; Asaoka T; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
PLoS One; 2016; 11(1):e0145985. PubMed ID: 26726879
[TBL] [Abstract][Full Text] [Related]
17. ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-kB-dependent activation of Snail.
Cichon MA; Radisky DC
Oncotarget; 2014 May; 5(9):2827-38. PubMed ID: 24811539
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
19. Upregulated expression of MMP family genes is associated with poor survival in patients with esophageal squamous cell carcinoma via regulation of proliferation and epithelial‑mesenchymal transition.
Xu G; Ou L; Liu Y; Wang X; Liu K; Li J; Li J; Wang S; Huang D; Zheng K; Wang S
Oncol Rep; 2020 Jul; 44(1):29-42. PubMed ID: 32627007
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.
Chaudhary AK; Singh M; Bharti AC; Asotra K; Sundaram S; Mehrotra R
J Biomed Sci; 2010 Feb; 17(1):10. PubMed ID: 20152059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
